MEMahyar Etminan

Mahyar Etminan

*This is an algorithmically generated author record based on publicly available information.

Mahyar Etminan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 August 2017
      • Vol. 83

    Dentists’ Prescribing of Analgesics for Children in British Columbia, Canada

    by Mahyar Etminan, M Reza Nouri, Mohit Sodhi, Bruce C Carleton

    Recently, there has been great interest in the use, abuse and over-prescribing of opioid analgesics for children. However, there is a paucity of evidence on patterns of prescribing of both narcotic and non-narcotic analgesics for children by dentists. We used a population-wide prescription drug database (PharmaNet) in British Columbia, Canada, to examine prescribing and dispensing of analgesics surrounding dental procedures. We examined all drugs prescribed for children by dentists between 1997 and 2013, as we had access to data on drug doses and days of medication supply. We also examined trends in the use of various narcotic and non-narcotic analgesics and benzodiazepines. In total, 268 691 children were prescribed at least 1 study drug by a dentist. Codeine was the most frequently prescribed: 50% of children received codeine for more than 3 days. Duration of use of codeine was greatest among children ≥12 years, the longest duration of use being 5 days. Our study reveals that codeine prescription by dentists increased over the 16-year study period. Codeine is prescribed by dentists for 50% of children; prescriptions are for too long a duration to avoid potential morphine accumulation and are not in line with current treatment guidelines.


  • Reply

    by Zaid Mammo, Michael Guo, David Maberley, Joanne Matsubara, Mahyar Etminan


  • Open Access

    Risk of intracranial hypertension with intrauterine levonorgestrel

    by Mahyar Etminan, Hao Luo, Paul Gustafson

    Objectives: The objective of this study was to quantify the risk of intracranial hypertension (ICH) with the intrauterine levonorgestrel (IUL) device Mirena®. Methods: We used the United States Food and Drug Administration’s Adverse Events Reporting System (FAERS) database to quantify a reporting odds ratio (ROR) for ICH and Mirena®. We also conducted a retrospective cohort study using the IMS LifeLink® database, comparing the risk of two oral contraceptives ethinyl estradiol (EE) with Mirena®. A Bayesian sensitivity analysis was performed to account for the effect of body mass index (BMI). Results: The reported odds ratios (ORs) for ICH and papilledema with Mirena® were 1.78 (95% confidence interval [CI] 1.41–2.25) and 1.50 (95% CI 1.10–2.05), respectively. In the cohort study, the OR for ICH and EE-norgestimate and EE-norethindrone compared with Mirena® were 1.29 (95% CI 0.83–2.00) and 0.31 (95% CI 0.04–2.29), respectively. The presence of a strong confounder BMI did not affect the estimated OR (OR = 1.31, 95% CI 0.73–2.41 for EE-norgestimate; OR = 0.18, 95% CI 0.01–1.27 for EE-norethindrone). Conclusion: We found a higher than expected number of reports of ICH with Mirena® in the FAERS database. We also found a similar risk of ICH with Mirena® compared with the oral contraceptive EE-norgestimate. The higher risk of ICH with EE-norethindrone, another oral contraceptive should be further investigated.


  • Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study

    by Mahyar Etminan, Sean C. Skeldon, Sheldon Larry Goldenberg, Bruce Carleton, James M. Brophy

    Background: Recent studies have provided conflicting and controversial results about the risk of cardiovascular events, including myocardial infarction (MI), with testosterone replacement therapy (TRT). The potential adverse effects of different TRT formulations and duration of therapy on MI risk are unknown.Methods: We performed a case‐control study within a cohort of 934,283 men aged 45–80 from the IMS LifeLink Health Plan Claims Database. For each case of MI, four controls were identified using density‐based sampling. Rate ratios (RRs) were computed for current and past TRT users. As a sensitivity analysis, the risk of MI before and after the start of a first‐time TRT prescription in the same patient was also computed.Results: We identified 30,066 MI cases and 120,264 corresponding controls. Current use of TRT was not associated with an increased risk of MI (RR 1.01, 95% confidence interval [CI] 0.89–1.16); first‐time users did show an increased risk (RR 1.41, 95% CI 1.06–1.87; number needed to harm 305). There was no association between MI and past TRT users and no differences among the different formulations. The RRs for current use and first‐time use of TRT in men with a previous history of coronary artery disease were 1.05 (95% CI 0.79–1.41) and 1.78 (95% CI 0.93–3.40), respectively.Conclusion: In this large observational study, an association between MI and past or current TRT use was not found. However, a statistically significant association was observed between first‐time TRT exposure and MI, although the absolute risk was low.


  • Open Access

    Risk for Uveitis With Oral Moxifloxacin

    by Brennan Eadie, Mahyar Etminan, Frederick S. Mikelberg

    Oral fluoroquinolones (FQs) are one of the most commonly prescribed classes of antibiotics in the United States. In 2011, an estimated 23 million prescriptions for oral FQs were written in the United States.1 Oral moxifloxacin hydrochloride (Avelox) is a broad-spectrum, third-generation FQ with high oral bioavailability that is commonly prescribed for the outpatient treatment of pneumonia.


  • Antibiotics and sudden death in adults taking renin-angiotensin system blockers

    by Mahyar Etminan, James M Brophy

    Is there a cause for concern? Adverse drug reactions have been associated with up to 10% of hospital admissions in older adults,1 a considerable number of which involve drug-drug interactions. Traditionally, information about drug-drug interactions was of poor quality, usually isolated case reports or small uncontrolled case series, resulting in much uncertainty about any clinical relevance. In recent years, large administrative databases that are linkable to health outcomes data have allowed investigators to better quantify rare drug-drug interactions and examine their effect on both morbidity and mortality. In the linked paper (doi:10.1136/bmj.g6196), Fralick and colleagues examined the risk of sudden death in users of both co-trimoxazole and renin-angiotensin system blockers (RASBs), two potassium sparing drugs.2 In an earlier study, the same authors reported that their joint administration was associated with a sevenfold increase in the risk of hyperkalemia induced hospital admission compared with RASB users exposed to other antibiotics.3 The new paper considers this same cohort of older RASB users from Ontario’s administrative databases, but now extends follow-up to 18 years and uses a nested case-control approach. The authors report adjusted odds ratios describing the risk of …


  • Risperidone Use and Risk for Gynecomastia in Men

    by Mahyar PharmD Etminan, Benji Heran, Bruce Carleton, James M. Brophy


  • Oral fluoroquinolone use and risk of peripheral neuropathy

    by Mahyar Etminan, James M. Brophy, Ali Samii

    Objective: To quantify the risk of peripheral neuropathy (PN) with oral fluoroquinolone (FQ) use. Methods: We conducted a case-control study within a cohort of men aged 45 to 80 years in the United States followed from 2001 to 2011. Cases were defined as those with the first physician visit diagnosis of PN, polyneuropathy, or drug-induced polyneuropathy. Four controls were matched to each case by age, follow-up, and calendar time using density-based sampling. As a sensitivity analysis, we also quantified the risk of PN with finasteride use, a drug that is not expected to increase the risk of PN. Rate ratios (RRs) for current users of FQs were computed using conditional logistic regression, which was adjusted for chronic renal failure, chronic liver disease, hypothyroidism, postherpetic neuralgia, and the use of nitrofurantoin and metronidazole. Results: We identified 6,226 cases and 24,904 controls. Current users of FQs were at a higher risk of developing PN (RR = 1.83, 95% confidence interval [CI] 1.49–2.27). Current new users had the highest risk (RR = 2.07, 95% CI 1.56–2.74). No risk was observed for current users of finasteride (RR = 1.21, 95% CI 0.97–1.51). Conclusions: Current users, especially new users of FQs, are at a higher risk of developing PN. Despite the increase in the use of FQs, clinicians should weigh the benefits against the risk of adverse events when prescribing these drugs to their patients.


  • Reporting guidelines for pharmacoepidemiological studies are urgently needed

    by Mahyar Etminan

    Tan and colleagues discuss factors that contribute to inconsistent information on drug adverse reactions but do not mention the lack of reporting guidelines for pharmacoepidemiological studies.1 Most medical journals require authors to complete checklists that are shortened versions of reporting guidelines, such as CONSORT (randomised trials), PRIMSA (systematic reviews), and …